Obesity, type 2 diabetes and risk of digestive cancer;Obesité, diabète de type 2 et risque de cancer du tube digestif.

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 10, 2010, Pages 529-533

  Hillon, P ^a,b   Guiu, B ^b   Vincent, J ^b   Petit, J M ^b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RISK; COLON CANCER; CYTOKINE RELEASE; DIGESTIVE SYSTEM CANCER; EXERCISE; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER CELL CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROGNOSIS; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RISK MANAGEMENT; SHORT SURVEY; TUMOR PROMOTION;

ADIPOKINES; ADIPOSE TISSUE; BIOLOGICAL FACTORS; BODY MASS INDEX; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FRANCE; GASTROINTESTINAL NEOPLASMS; HUMANS; INCIDENCE; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; METALLOPROTEASES; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SERINE PROTEINASE INHIBITORS; WORLD HEALTH;

EID: 78049240531     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.07.021     Document Type: Short Survey

References (48)

1. Pischon T., Boeing H., Hoffmann K., et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008, 359:2105-2120.
2. Polendnak A.P. Estimating the number of US incident cancers attributable to obesity and the impact of temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev 2008, 32:190-199.
3. van Kruijsdijk R., Van der Wall E., Visseren F. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009, 18:2569-2578.
4. Hartz A.J., Rupley D.C., Kalkhoff R.D., Rimm A.A. Relationship of obesity to diabetes: influence of obesity level and body fat distribution. Prev Med 1983, 12:351-357.
5. Kahn S.E., Hull R., Utzschneider R. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
6. Munzberg H., Myers M.G. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005, 8:566-570.
7. Stattin P., Lukanova A., Bieey C., et al. Obesity and colon cancer: does leptin provide a link?. Int J Cancer 2004, 109:149-152.
8. Tamakoshi K., Toyoshima H., Wakai K., et al. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology 2005, 68:454-461.
9. Hoda M.R., Keely S.J., Bertelsen L.S., et al. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007, 94:346-354.
10. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
11. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57:25-40.
12. Mutoh M., Niho N., Komiya M., et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008, 29:824-829.
13. Sakakibara T., Hibi K., Koike M., et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005, 93:799-803.
14. Hilska M., Roberts P.J., Collan Y.U., et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007, 121:714-723.
15. Cho Y.B., Lee W.Y., Song S.Y., et al. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 2007, 38:1603-1610.
16. Tian M., Cui Y.Z., Song G.H., et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 241:1-11.
17. Yokoyama M., Ochi K., Ichimura M., et al. Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 2002, 24:344-347.
18. Jones L.E., Humphreys M.J., Campbell F., et al. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004, 10:2832-2845.
19. Grutzmann R., Luttges J., Sipos B., et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004, 90:1053-1058.
20. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27:5287-5297.
21. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
22. Heikkila K., Harris R., Lowe G., et al. Associations of circulating C reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2008, 20:15-26.
23. Balkwill F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev 2006, 25:409-416.
24. Katiyar S.K., Meeran S.M. Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-κB signaling. Free Radic Biol Med 2007, 42:299-310.
25. Giovannucci E., Ascherio A., Rimm E.B., Colditz G.A., Stampfer M.J., Willett W.C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995, 122:327-334.
26. Hu F.B., Willett W.C., Li T., et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004, 351:2694-2703.
27. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer 2008, 8:205-211.
28. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003, 348:1625-1638.
29. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
30. Bergström A., Pisani P., Tenet V., Wolk A., Adami H.O. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001, 91:421-430.
31. Reeves G.K., Pirie K., Beral V., Green J., Spencer E., Bull D. Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 2007, 335:1134-1145.
32. Polednak A.P. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev 2008, 32:190-199.
33. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
34. Ogunleye A.A., Ogston S.A., Morris A.D., Evans J.M.M. Cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 2009, 101:1199-1201.
35. Kuriki K., Hirose K., Tajima K. Diabetes and cancer risk for all specific sites among Japanese men and women. Eur J Cancer Prev 2007, 7:89-107.
36. Swerdlow A.J., Laing S.P., Qiao Z., et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005, 92:2070-2075.
37. El-Serag H.B., Tran T, Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
38. Davila J.A., Morgan R.O., Shaib Y., McGlynn K.A., El-Serag H.B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population-based case-control study. Gut 2005, 54:553-559.
39. Huxley R., Ansary-Moghaddam A., Berrington de Gonzalez A., Barzi F., Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92:2076-2083.
40. Larsson S.C., Orsini N., Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:1679-1687.
41. Inoue M., Iwasaki M., Otani T., Sasazuki S., Noda M., Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006, 166:1871-1877.
42. Saito K., Inoue S., Saito T., et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002, 51:100-104.
43. Komura T., Mizukoshi E., Kita Y., et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007, 102:1939-1946.
44. Ohki T., Tateishi R., Shiina S., et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009, 58:839-844.
45. Oka R., Kobayashi J., Yagi K., et al. Reassessment of the cut-off values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract 2008, 79:474-481.
46. Guiu B., Petit J.M., Bonnetain F., et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010, 59:341-347.
47. Silha J.V., Krsek M., Sucharda P., Murphy L.J. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 2005, 29:1308-1314.
48. Miyazawa-Hoshimoto S., Takahashi K., Bujo H., Hashimoto N., Saito T. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003, 46:1483-1488.